Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Brand Names
- Prevnar 13, Prevnar 20, Vaxneuvance
- Generic Name
- Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
- DrugBank Accession Number
- DB10287
- Background
Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 6b individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197). It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection. The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Conjugate - Synonyms
- Streptococcus pneumoniae serotype 6B capsular antigen diphtheria CRM197 protein conjugate vaccine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image PREVENAR 0.5 ML ENJEKSIYON ICIN SUSPANSIYON ICEREN KULL.HAZ.ENJEKTOR, 1 ADET Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen (4 μg) + Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (2 μg) + Streptococcus pneumoniae type 18C capsular polysaccharide diphtheria CRM197 protein conjugate antigen (2 μg) + Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen (2 μg) + Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen (2 μg) + Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (2 μg) + Streptococcus pneumoniae type 9V capsular polysaccharide diphtheria CRM197 protein conjugate antigen (2 μg) Suspension Intramuscular PFİZER İLAÇLARI LTD. ŞTİ. 2020-08-14 2022-04-11 Turkey 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4M543JVT7G
- CAS number
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Acute Lymphoblastic Leukaemias (ALL) 1 4 Completed Prevention Asthma 2 4 Completed Prevention Bone Marrow Transplant (BMT) 1 4 Completed Prevention Hepatitis A Virus 1 4 Completed Prevention Human Immunodeficiency Virus (HIV) Infections / Invasive Pneumococcal Disease (IPD) / Meningitis / Pneumonia 1 4 Completed Prevention Pneumococcal Infection / Pneumonia / Streptococcus Pneumoniae Infections 1 4 Completed Treatment Pain 1 4 Terminated Treatment Primary Immunodeficiency 1 4 Unknown Status Prevention Transplant 1 3 Active Not Recruiting Prevention Acute Otitis Media (AOM) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, suspension Intramuscular Suspension Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:03 / Updated at August 13, 2021 20:47